Avapritinib (Ayvakit) for GIST

Date: February 8, 2021 Issue #:  1617Summary:  The FDA has approved the oral tyrosine kinase inhibitor avapritinib (Ayvakit– Blueprint Medicines) for treatment of unresectable or metastatic gastrointestinal stromal tumors (GISTs) harboring a platelet-derived growth factor receptor alpha (PDGFRA) D842V or other PDGFRA exon 18 mutation. Avapritinib is the first drug to be approved for this indication in the US.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: avapritinib Ayvakit GIST Gleevec Imatinib regorafenib Stivarga sunitinib Sutent Source Type: research